Illumina: Kathryne Reeves
Illumina has announced that Kathryne Reeves will join the firm as chief marketing officer on Sept. 28, 2020, reporting to CEO Francis deSouza.
Reeves brings more than 25 years of marketing and management experience and comes to Illumina from Cardinal Health, where she was senior VP of enterprise marketing and general manager of the medical services global business unit. Prior to that, she held positions at Booz Allen Hamilton, AOL/TimeWarner, Nationwide Insurance, and Scotts Miracle-Gro.
Reeves holds an MBA from Harvard Business School.
Biocept: Michael Dugan
Biocept has appointed Michael Dugan as chief medical officer and medical director, responsible for medical policy decision-making and operations of Biocept's CLIA-certified laboratory. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics International. Before that, he was senior medical advisor and chief medical officer of Clinical Genomics. He has also served as senior VP of clinical development and medical affairs at Exact Sciences, medical director at Quest Diagnostics Nichols Institute, chief medical officer at BioTheranostics, VP and chief medical officer at Roche Molecular Systems, and VP of pathology services at Genzyme Genetics.
Dugan received a BS in biology from the University of Notre Dame and a medical degree from the University of Arizona College of Medicine. He completed his post-graduate training in the department of pathology at Yale-New Haven Hospital and in the departments of pathology and laboratory medicine at Childrens Hospital Los Angeles and the University of California, Los Angeles.
Immunovia: Patrik Dahlen, Mats Grahn
Immunovia appointed Patrik Dahlen as its new CEO starting Nov. 1. Dahlen succeeds Mats Grahn, who has been nominated as a member of Immunovia's board.
Dahlen has served as CEO of several diagnostic companies. As CEO of Dako, he implemented a strategic repositioning of the company as a supplier of cancer diagnostics, which resulted in its acquisition by Agilent Technologies for $2.2 billion. As president of life sciences at Perkin Elmer, he was instrumental in building the company's diagnostics business with a niche focus on diagnostic systems for neonatal and prenatal screening.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.